Antares Pharma, Inc. (ATRS) Analysts See $-0.02 EPS

October 13, 2018 - By Peter Erickson

Investors sentiment increased to 1.41 in 2018 Q2. Its up 0.61, from 0.8 in 2018Q1. It is positive, as 9 investors sold Antares Pharma, Inc. shares while 20 reduced holdings. 15 funds opened positions while 26 raised stakes. 59.50 million shares or 6.29% more from 55.98 million shares in 2018Q1 were reported.
State Board Of Administration Of Florida Retirement Sys, a Florida-based fund reported 59,413 shares. Chevy Chase Inc, a Maryland-based fund reported 15,000 shares. California State Teachers Retirement stated it has 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Perkins Capital Incorporated owns 317,500 shares. Bank Of New York Mellon Corp has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). California Employees Retirement has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 483,600 shares. 10,000 are held by Us Comml Bank De. Raymond James Fincl Advsrs has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Royal Savings Bank Of Canada has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS). Jpmorgan Chase And stated it has 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Bnp Paribas Arbitrage, a New York-based fund reported 4,913 shares. Fuller & Thaler Asset holds 0.01% or 517,300 shares in its portfolio. Fincl Bank Of America Corp De owns 43,381 shares. Ballentine Lc accumulated 0.01% or 100,000 shares. Principal Fincl Inc invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS).

Since May 9, 2018, it had 0 buys, and 13 sales for $4.90 million activity. Another trade for 43,000 shares valued at $161,250 was sold by APPLE ROBERT F.

Analysts expect Antares Pharma, Inc. (NASDAQ:ATRS) to report $-0.02 EPS on November, 6.They anticipate $0.01 EPS change or 33.33 % from last quarter’s $-0.03 EPS. After having $-0.03 EPS previously, Antares Pharma, Inc.’s analysts see -33.33 % EPS growth. The stock decreased 1.18% or $0.04 during the last trading session, reaching $3.36. About 1.29 million shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 10.07% since October 13, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Antares Pharma, Inc. (NASDAQ:ATRS) Ratings Coverage

Among 2 analysts covering Antares Pharma (NASDAQ:ATRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 2 analyst reports since May 8, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Tuesday, May 8 with “Buy”. Raymond James maintained the shares of ATRS in report on Tuesday, October 2 with “Strong Buy” rating.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $528.99 million. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

More news for Antares Pharma, Inc. (NASDAQ:ATRS) were recently published by:, which released: “Here’s Why Antares Pharma Jumped Higher Today” on October 02, 2018.‘s article titled: “FDA OKs Antares Pharm’s TRT med Xyosted” and published on October 01, 2018 is yet another important article.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.